Early Onset Alzheimer'S Disease (Eoad) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Also known as: Early-Onset Alzheimer Disease (EOAD), Presenile Dementia, Young-Onset Alzheimer's Disease [1]
Definition: Early-onset Alzheimer's disease refers to Alzheimer's disease that develops before age 65, typically between 30-64 years of age. It represents approximately 5-10% of all Alzheimer's cases but accounts for a disproportionate burden of disease due to its impact on individuals in their working years.[2] [3]
Early-onset Alzheimer's disease affects approximately 200,000-250,000 Americans under age 65, representing about 5-10% of the total AD population.[1:1] The prevalence increases with age: [4]
Unlike late-onset AD, early-onset cases show no significant gender predilection, whereas late-onset AD disproportionately affects women.[3:1] [5]
Approximately 10-15% of early-onset AD cases are caused by autosomal dominant mutations in one of three genes:[4:1] [^6]
| Gene | Chromosome | Protein | Typical Onset | Key Mutations | [^7]
|------|------------|---------|---------------|---------------| [^8]
| APP | 21q21.3 | Amyloid Precursor Protein | 50-60 years | Swedish (K670N/M671L), London (V717I), Arctic (E693G) | [^9]
| PSEN1 | 14q24.3 | Presenilin-1 | 35-55 years | Over 200 mutations identified | [^10]
| PSEN2 | 1q42.13 | Presenilin-2 | 45-70 years | Less common than PSEN1 | [^11]
These mutations cause increased production of amyloid-beta 42/40 ratio, leading to early amyloid plaque formation.[5:1] [^12]
Early-onset AD often presents differently than late-onset AD:[^7] [^13]
Diagnosing early-onset AD presents unique challenges:[^9] [^14]
The same core biomarkers used in late-onset AD are applicable: [^15]
Genetic counseling and testing is recommended for:[^11]
The clinical course of early-onset AD tends to be more aggressive:[^12]
| Feature | Early-Onset AD | Late-Onset AD |
|---|---|---|
| Progression rate | Faster decline | Slower progression |
| Survival from onset | 6-8 years | 8-12 years |
| Functional impairment | More rapid | Gradual decline |
| Behavioral symptoms | Less common early | More prominent |
All FDA-approved Alzheimer's medications are indicated for early-onset AD:[^13]
NMDA receptor antagonist:
Disease-modifying therapies:
Early-onset AD patients are underrepresented in clinical trials despite their significant disease burden.[^15] Trial inclusion criteria often exclude patients under 60-65 years, limiting generalizability.
Research focuses on:
The study of Early Onset Alzheimer'S Disease (Eoad) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Blood serum from individuals with Alzheimer's disease alters microglial phagocytosis in vitro. ↩︎ ↩︎
AlzStack: Forecasting early-onset Alzheimer's with an explainable AI system using multiple data balancing techniques. ↩︎
Metabolic breakdown: Linking insulin resistance and mitochondrial dysfunction to neurodegeneration in Alzheimer's disease. ↩︎ ↩︎
Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration. ↩︎ ↩︎
ABCA7 rs115550680 risk allele carriers have lower medial temporal lobe dynamic network flexibility than APOE-ε4 allele carriers among older African Americans. ↩︎ ↩︎